Senior pharmaceutical figure calls on industry to improve its imageBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6733 (Published 24 November 2010) Cite this as: BMJ 2010;341:c6733
- Oliver Ellis
The former medical director of the drug company Wyeth UK has called on the industry to improve its reputation among doctors and to get more involved in training them.
David Gillen, who is now head of international medical affairs at Gilead Sciences, told the annual symposium last week of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK that academia, the NHS, and the drug industry should collaborate more.
“Trust needs to happen again,” he said. “Fundamentally most of us in this room represent industry, and fundamentally most of us …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial